Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Notice to Readers Diphtheria-Tetanus-Pertussis Vaccine Shortage

On February 12, 1985, the American Academy of Pediatrics hosted a meeting to discuss ways of dealing with the current shortage of diphtheria-tetanus-pertussis (DTP) vaccine. The meeting was attended by representatives of the American Medical Association; American Academy of Family Practice; the vaccine manufacturer; state, county, and city health officials; the U.S. Department of Defense; and the U.S. Department of Health and Human Services.

Available information indicates that, overall, state health departments have approximately 2.3 months' supply of DTP vaccine on hand, but this vaccine is not uniformly distributed, with 18 states having supplies on hand of 1 month or less. Because of close inventory monitoring and prudent use of DTP reserves held by the manufacturer, vaccine has remained available in the public sector to date.

A survey conducted by eight different state health departments of 583 physicians indicated approximately one-third had had difficulties in obtaining DTP vaccine, and approximately one-half were following the current recommendations to defer the DTP doses for 18-month-old and 4- to 6-year-old children. In four states, where inventory estimates were made, physicians' current inventories ranged from 1.9 to 2.9 months' supply.

Lederle Laboratories reported the release for distribution of one DTP vaccine lot on February 12. This lot, about 35,000 vials (525,000 doses), has been divided among the company's five regional distribution centers located in Los Angeles, California; Atlanta, Georgia; Chicago, Illinois; Philadelphia, Pennsylvania; and Dallas, Texas. This vaccine is being distributed to health-care providers now.

Because currently available supplies of DTP vaccine are limited, the manufacturer is carefully coordinating the distribution of vaccine to both public and private health-care providers. Following extensive discussions, the group reached the following conclusions and recommendations:

  1. Current information indicates that adequate supplies of DTP vaccine should become available in mid- or late 1985.

  2. Until adequate supplies become available, it is important to continue the currently recommended practice of deferring the DTP vaccine doses for 18-month-old and 4- to 6-year-old children to assure that the initial three-dose immunization schedule for infants is met.

  3. Practitioners should not administer partial doses of DTP vaccine in an effort to make the vaccine go further, since the degree of protection afforded by such partial doses is not certain.

  4. Diphtheria-tetanus vaccine should not be substituted in the routine DTP vaccine schedule for 18-month-old and 4- to 6-year-old children.

  5. It is important for practitioners to establish recall systems to ensure that children whose doses are deferred are recalled for the DTP vaccine they need once supplies become available.

  6. Because some children will have their 18-month or "preschool dose" of DTP vaccine deferred this spring and summer, it may be necessary for day-care centers or school systems to allow provisional enrollment of such children until they can receive the needed doses.

  7. As soon as adequate supplies become available, the Academy of Pediatrics and the U.S. Public Health Service will notify physicians so they can again resume the full DTP immunization schedule and recall those who need additional doses.

Reported by U.S. Public Health Service Interagency Group to Monitor Vaccine Development, Production, and Usage.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.


All MMWR HTML versions of articles are electronic conversions from typeset documents. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

 
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #